B+
Bull case
25%
Probability
Target price
$150.00
Analysis reference price unavailable
Analysis 2026-07-27 · RankAlpha Sentiment Codex
MNPR
Monopar TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$118.25
Analysis reference price unavailable
Analysis 2026-07-27 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$80.00
Analysis reference price unavailable
Analysis 2026-07-27 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-27
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+69.5
Score
AI commentary
The newly confirmed rolling NDA submission is a positive evidence update, but broad recent-news coverage, social context, analyst revisions, options data, short interest, employee sentiment, and post-event price-reaction attribution are unavailable. Sentiment is therefore cautiously positive but low-conviction, with monitoring focused on NDA completion and FDA status.
RankAlpha Sentiment Codex - 2026-07-27
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-22eventRolling ALXN1840 NDA submission initiatedHigh impact
Monopar reported in its July 22 Form 8-K that it initiated the rolling submission of an NDA for ALXN1840 in Wilson disease. This is a confirmed regulatory-progress milestone, although FDA acceptance and approval remain unconfirmed. [#8-K-2026-07-22]
2026-10-25eventRegulatory follow-through and FDA status updateHigh impact
Completion of the rolling NDA and subsequent FDA review-status updates could provide the next material valuation signal. Timing and outcome are unavailable, so this remains a monitoring catalyst rather than a high-confidence forecast.
2027-07-27catalystWilson disease commercialization pathHigh impact
The first-quarter release described positive Phase 3 FoCus analyses, commercial-readiness activities, and plans for ALXN1840 regulatory and potential commercial activity; cash, cash equivalents, and investments were reported at $137.5 million with funds expected to support operations through at least December 31, 2027. Approval, launch execution, and adoption remain uncertain. [#PR-EARNINGS-2026-05-15] [#SEC-8K-2026-05-14]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-27 • Updated nightlySource: Internal modelMethodology